The World Health Organization’s Solidarity PLUS trial will kick off in 52 countries, trialing three drugs to treat patients hospitalized with COVID-19.
The clinical study network is partnering with the Wisconsin-based health system to increase the reach of trials into a largely rural patient population.
This month’s news on hires, promotions, acquisitions, expansions, and funding includes items about Syneos Health, ProSciento, Phastar, CPhI, Immunai, and other key industry players.
The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.
The World Health Organization hopes to encourage the development of novel therapies for tuberculosis by spotlighting key clinical study characteristics.
The oncology-centered analytics firm will work with the DC-area healthcare provider to delve into discovery and development of novel cancer treatments.
A representative from the medication management solutions company suggests patient behavior data can be used to improve adherence to trial drug regimens.
According to a leader from CRO Quanticate, the research industry’s increased use of real-world data is leading to a broad range of benefits in trial work.
A leader from life-sciences IT consultancy Daelight Solutions shares how the clinical trial data landscape has changed and offers advice on how to keep up.
The company’s ryze technology combines a clinical MDR and study automation platform, designed to accelerate and optimize design and execution of trials.
These organizations hope to connect with attendees at the event, sharing clinical research ideas and innovations in sessions and the virtual exhibit hall.
The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drug’s effectiveness in preventing worsening of symptoms and hospitalization.
Acting FDA commissioner Janet Woodcock explains how government, researchers, doctors and patients can contribute to improving the clinical research system.
According to a leader from the pharma firm, considering a patient’s needs and seeing them as a whole person is vital to successful studies and drug design.
A leader from the clinical trial technology firm suggests ways to design research from the start to help accelerate studies and avoid stumbling blocks.
In this third part of a series on the state of clinical research, the acting FDA commissioner talks about possible pathways to improving the infrastructure.
A leader from clinical-stage pharma firm NuCana shares promising results for its ProTides therapies and hopes the drugs can elevate outcomes for patients.
Interim data reportedly indicates Noxopharm’s Veyonda could be effective in treating cytokine storm, an inflammatory effect associated with moderate cases.
A leader from oncology trial insights and analysis specialist Inteliquet discusses how cancer studies can recover after the impact of the global pandemic.
Organicell has announced the initial results from its India-based trial of the COVID-19 treatment Zofin look promising, plans to expand to more patients.
The trial technology provider and contract research organization will collaborate on tech and process solutions designed to accelerate clinical studies.
In this second part of a series on the state of clinical research, a leader from Javara lays out ideas to bring clinical research and care closer together.
In this first part of a series on the state of clinical research, an expert shares insightful ideas on how to improve patient experience and study results.
The two companies plan to collaboratively explore ways to combine 3D printing and nanotechnology, in order to create nanoparticle-enabled dosage forms.
The 6th annual Clinical Research as a Care Option conference, taking place April 26-27, brings together experts seeking solutions to elevate the industry.
Artelo Biosciences is investigating the viability of its novel cannabinoid product as a solution to treat cancer-related anorexia in oncology patients.
One Health’s FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.
The two companies have partnered to develop a systemic erythematosus assessment review to streamline clinical trials centered on the autoimmune disease.
The AWARE for All virtual event series aims to educate and engage the public as important partners in clinical trials and development of new treatments.
A father of two boys with Duchenne muscular dystrophy is running the Austin Marathon to raise funds toward pursuit of a cure for the rare, fatal disease.
A leader from the trial solutions provider discusses how the COVID-19 pandemic has accelerated the already growing interest in remote patient monitoring.
The CRO will receive funding to fuel a five-year Research Project Award, with the goal to design and conduct research of potential PTSD treatment options.
The collaboration will leverage patients’ biological and medical data to streamline patient identification and recruitment efforts in clinical research.
A senior clinical research associate from the CRO discusses how the pandemic has touched her workday, and how she is dealing with the myriad challenges.
In the drive to advance personalized medicine, researchers are increasingly turning to radiomics to assist in the discovery of new types of biomarkers.
The founder of Andaman7’s leukemia diagnosis, and his son’s experience with bone cancer, have helped inform the firm's tech and patient-centric approach.
The two companies are integrating their technologies in a move designed to help hasten trial launches, and get promising new treatments to market faster.
Bioclinica’s Image Redact AI tool enables trials to edit sensitive information from videos, photos and PDFs to ensure compliance and safeguard patient data
While the change signifies the life-sciences solutions firm’s commitment to help customers and patients, day-to-day functions will remain much the same.
Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.